

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT		
NATURE OF CONVEYANCE:	Corrective Assignment to correct the nature of conveyance previously recorded on Reel 003235 Frame 0636. Assignor(s) hereby confirms the Assignment.		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Elan Pharmaceuticals, Inc.		03/13/2007	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	Acorda Therapeutics, Inc.		
Street Address:	15 Skyline Drive		
City:	Hawthorne		
State/Country:	NEW YORK		
Postal Code:	10532		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Serial Number:	78713378	ZANAFLEX CAPSULES	
Registration Number:	1906277	ZANAFLEX	
Registration Number:	2383531	ZANAFLEX	
CORRESPONDENCE DATA			
Fax Number:	(312)554-8015		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
Phone:	312-554-8000		
Email:	kjl@pattishall.com		
Correspondent Name:	Pattishall McAuliffe Newbury Hilliard et		
Address Line 1:	311 S. Wacker Drive		
Address Line 2:	Suite 5000		
Address Line 4:	Chicago, ILLINOIS 60606		
ATTORNEY DOCKET NUMBER:	03060-00001		
NAME OF SUBMITTER:	Sanjiv D. Sarwate		

CH \$90.00 78713378

Signature:

/Sanjiv D. Sarwate/

Date:

11/13/2007

Total Attachments: 6

source=ZANAFLEX CAPSULES#page1.tif

source=ZANAFLEX CAPSULES#page2.tif

source=ZANAFLEX CAPSULES#page3.tif

source=ZANAFLEX CAPSULES#page4.tif

source=ZANAFLEX CAPSULES B#page1.tif

source=ZANAFLEX CAPSULES B#page2.tif

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	TRADEMARK LICENSE		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Elan Pharmaceuticals, Inc.		07/21/2004	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	Acorda Therapeutics, Inc.		
Street Address:	15 Skyline Drive		
City:	Hawthorne		
State/Country:	NEW YORK		
Postal Code:	10532		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Registration Number:	1906277	ZANAFLEX	
Registration Number:	2383531	ZANAFLEX	
Serial Number:	78713378	ZANAFLEX CAPSULES	
CORRESPONDENCE DATA			
Fax Number:	(703)816-4100		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
Phone:	703-816-4057		
Email:	wfg@nixonvan.com		
Correspondent Name:	Willem F. Gadiano		
Address Line 1:	Nixon & Vanderhye P.C.		
Address Line 2:	901 North Glebe Road, 11th Floor		
Address Line 4:	Arlington, VIRGINIA 22203		
ATTORNEY DOCKET NUMBER:	4379-13		
NAME OF SUBMITTER:	Willem F. Gadiano		

CH \$90.00 1906277

900040822

TRADE MARK
 REEL: 003235 FRAME: 636

TRADE MARK
 REEL: 003660 FRAME: 0179

Signature:

/wfgadiano/

Date:

01/27/2006

Total Attachments: 15

source=4379-13 tm license#page1.tif
source=4379-13 tm license#page2.tif
source=4379-13 tm license#page3.tif
source=4379-13 tm license#page4.tif
source=4379-13 tm license#page5.tif
source=4379-13 tm license#page6.tif
source=4379-13 tm license#page7.tif
source=4379-13 tm license#page8.tif
source=4379-13 tm license#page9.tif
source=4379-13 tm license#page10.tif
source=4379-13 tm license#page11.tif
source=4379-13 tm license#page12.tif
source=4379-13 tm license#page13.tif
source=4379-13 tm license#page14.tif
source=4379-13 tm license#page15.tif

**TRADEMARK
REEL: 003235 FRAME: 0637**

**TRADEMARK
REEL: 003660 FRAME: 0180**

TRADEMARK ASSIGNMENT AND PURCHASE AGREEMENT

(ZANAFLEX®)

This TRADEMARK ASSIGNMENT AND PURCHASE AGREEMENT dated as of March 13, 2007 (the "Assignment"), by and between Elan Pharmaceuticals, Inc., a Delaware corporation, having offices at 800 Gateway Boulevard, South San Francisco, California 94080 ("Assignor") and Acorda Therapeutics, Inc., a Delaware corporation, having its principal offices at 15 Skyline Drive Hawthorne, NY 10532 ("Assignee").

BACKGROUND

A. Assignor's predecessor in interest adopted, used, and Assignor is presently the owner of the entire right, title and interest in and to the ZANAFLEX trademarks registered with the United States Patent and Trademark Office in connection with its pharmaceutical business in the United States, including registrations and applications therefor, identified in Schedule A attached hereto, and all goodwill associated therewith (hereinafter the "Trademark");

B. Assignee, presently using the Trademark under license, desires to acquire Assignor's entire right, title, and interest in and to the Trademark and all goodwill associated therewith, having satisfied the conditions pursuant to the Asset Purchase Agreement (hereinafter the "Purchase Agreement"), dated July 21, 2004.

C. Assignor makes this Assignment pursuant to that certain Purchase Agreement, by and among Assignor and Assignee, under which Assignee purchased certain Purchased Assets (as defined therein) from Assignor, including but not limited a license to the Trademark and the products covered thereby; and

D. NOW, THEREFORE, for good and valuable consideration stated in the Purchase Agreement, the receipt and adequacy of which is hereby acknowledged, the parties agree as follows:

1. Assignor hereby sells, transfers, conveys, assigns and delivers to Assignee, and Assignor hereby purchases, acquires and accepts from Assignor, all of Assignor's and each such Affiliate's right, title and interest, as of the date hereof, in and to the Trademark in the United States, together with all of the goodwill associated with the Trademark, free and clear of any Encumbrances as defined in the Purchase Agreement (other than Permitted Encumbrances as defined in the Purchase Agreement).

2. Assignor will from time to time, at the request of Assignee, execute and deliver, or cause its Affiliates to execute and deliver, such other instruments of conveyance and transfer and take such other actions as Assignee may reasonably request, in order to more effectively consummate the transactions contemplated hereby and to vest in Assignee good and marketable title to the Trademark.

3. Except as set forth in the Purchase Agreement, Assignor makes no warranty, express or implied, with respect to the Trademark involved in this Assignment and Assignee shall have no recourse against Assignor therefor.

4. Assignee shall record this Assignment or any other document or transfer with the United States Patent and Trademark Office, Assignee shall bear the costs and fees associated with recording, but Assignor shall provide timely cooperation to Assignee as reasonably necessary.

5. Notwithstanding any other provisions of this Assignment to the contrary, nothing contained in this Assignment shall in any way supersede, modify, replace, amend, change, rescind, waive,

M

exceed, expand, enlarge or in any way affect the provisions, including warranties, covenants, agreements, conditions, representations, or in general any of the rights and remedies, and any of the obligations and indemnifications of Seller or Buyer set forth in the Purchase Agreement nor shall this Assignment expand or enlarge any remedies under the Purchase Agreement including without limitation any limits on indemnification specified therein. This Assignment is intended only to effect the transfer of certain property transferred pursuant to the Purchase Agreement and shall be governed entirely in accordance with the terms and conditions of the Purchase Agreement.

6. This Assignment shall in all respects be construed in accordance with and governed by the laws of the State of New York without giving effect to its conflicts-of-laws principles.

7. This Assignment may be executed in any number of counterparts and by facsimile and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute but one and the same agreement.

[SIGNATURE PAGE TO FOLLOW]

M

IN WITNESS WHEREOF, each party has caused its proper officer to execute this Trademark Assignment effective as of March 13, 2007.

ELAN PHARMACEUTICALS, INC.

By: Richard T. Collier
Name: Richard T. Collier
Title: Secretary/EVP

ACORDA THERAPEUTICS, INC.



By: [Signature]
Name: RAFFISHER
Title: CEO

[SIGNATURE PAGE TO TRADEMARK ASSIGNMENT
(ZANAFLEX)]

TRADEMARK
REEL: 003660 FRAME: 0183

M

SCHEDULE A
TRADEMARK ASSIGNMENT

Trademark	Reg No./App No.	Country	Date of Registration
ZANAFLEX ®	Reg No. 1906277	United States	July 18, 1995
ZANAFLEX ®	Reg No. 2383531	United States	September 5, 2000
ZANAFLEX CAPSULES®	App No. 78713378	United States	Filing date: September 15, 2005

SCHEDULE A